Shares of BriaCell Therapeutics Corp. (CVE:BCT – Get Free Report) were down 3.8% on Monday . The stock traded as low as C$10.60 and last traded at C$10.60. Approximately 3,402 shares changed hands during mid-day trading, a decline of 73% from the average daily volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Price Performance
The company has a market capitalization of C$168.68 million and a PE ratio of -28.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 128.68 and a current ratio of 129.63. The stock has a 50 day moving average price of C$10.60 and a two-hundred day moving average price of C$10.60.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
See Also
- Five stocks we like better than BriaCell Therapeutics
- 3 Small Caps With Big Return Potential
- AbbVie Stock: A Perfect Dip for Investors to Buy
- How Technical Indicators Can Help You Find Oversold Stocks
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- 3 Tickers Leading a Meme Stock Revival
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.